Vesper Bio
Denmark - CopenhagenBiotechnology
Focus: Vesper Bio is a Copenhagen-based public biotech company focused on oral therapies for frontotemporal dementia, operating at the intersection of oncology and neurology. The company is in early-stage clinical development with limited public pipeline visibility.
Profile data last refreshed 1h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
3+3 this month
Stable — net +3 jobs in 30d
5 added, 2 removed. Backfill posture.
Should You Work at Vesper Bio?
AI assessmentVesper Bio presents a niche, focused opportunity for candidates betting on rare-disease neurology and willing to accept early-stage execution risk for public-company stability.
Why Work Here
- Public company status provides stability, equity upside potential, and clearer career advancement pathways versus early-stage private firms.
- Focused pipeline in high-need neurology space (frontotemporal dementia) positions you on a potentially high-impact therapeutic area with limited competitive saturation.
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Vesper Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.